Results 51 to 60 of about 1,123,126 (369)

Leukemia cutis

Indian Journal of Dermatology, 2012
Leukemia cutis is the infiltration of neoplastic leukocytes or their precursors into the epidermis, the dermis, or the subcutis, resulting in clinically identifiable cutaneous lesions. Leukemia cutis may follow, precede or occur concomitantly with the diagnosis of systemic leukemia.
Angoori G Rao, Indira Danturty
openaire   +3 more sources

KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

Molecular Oncology, EarlyView.
We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock, Lina Benzien, Sandra Lange, Maja Huehns, Alexandra Runge, Catrin Roolf, Anett Sekora, Gudrun Knuebel, Hugo Murua Escobar, Christian Junghanss, Anna Richter   +10 more
wiley   +1 more source

The clathrin-binding domain of CALM-AF10 alters the phenotype of myeloid neoplasms in mice. [PDF]

, 2012
The PICALM (CALM) gene, whose product is involved in clathrin-mediated endocytosis, has been identified in two recurring chromosomal translocations, involving either MLL or MLLT10 (AF10). We developed a mouse model of CALM-AF10(+) leukemia to examine the
Anastasi, J, Brodsky, FM, Fernald, AA, Le Beau, MM, Stoddart, A, Tennant, TR   +5 more
core   +2 more sources

Polyfunctional CD8+CD226+RUNX2hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia

Molecular Oncology, EarlyView.
CD226+CD8+ T cells express elevated levels of RUNX2, exhibit higher proliferation capacity, cytokines and cytolytic molecules expression, and migratory capacity. In contrast, CD226−CD8+ T cells display an exhausted phenotype associated with the increased expression of co‐inhibitory receptors and impaired effector functions.
Maryam Rezaeifar, Shima Shahbaz, Anthea C. Peters, Spencer B. Gibson, Shokrollah Elahi   +4 more
wiley   +1 more source

Patient Attitudes Toward Genetic Testing for Inherited Predispositions to Hematologic Malignancies [PDF]

, 2018
Although inherited predispositions to hematologic malignancies have previously been considered extremely rare, approximately 12 causative genes have been implicated in the last decade.
Beecroft, Taylor
core   +1 more source

Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies. [PDF]

, 2015
Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists.
Biassoni, Biron, Björklund, Brodin, Bryceson, Burns, Campbell, Cooley, Cooper, Cooper, Curti, Davies, Di Santo, Di Santo, Farag, Fehniger, Fogler, Foley, Freud, Gasser, Gilfillan, Grimm, Guethlein, Herberman, Huntington, Joncker, Kiessling, Killig, King, Kröger, Lajoie, Lanier, Leong, Ljunggren, Lowe, Lundqvist, Mancusi, McQueen, Miller, Moretta, Moretta, Moretta, Nguyen, Oevermann, Ouyang, Perussia, Phillips, Romagnani, Romee, Rosenberg, Rosenberg, Rosenberg, Ruggeri, Santoni, Stabile, Stabile, Stern, Stringaris, Thielens, Torelli, Trinchieri, Trinchieri, Vago, Valés-Gómez, Venstrom, Vivier, Whitelaw, Zorn   +67 more
core   +1 more source

Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction

Molecular Oncology, EarlyView.
Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy, Heather Fairfield, Victoria E. DeMambro, Samaa Fadel, Carlos A. Gartner, Michelle Karam, Christian Potts, Princess Rodriguez, Ya‐Wei Qiang, Habib Hamidi, Xiangnan Guan, Calvin P. H. Vary, Michaela R. Reagan   +12 more
wiley   +1 more source

Classical meets malignant hematology: a case of acquired εγδβ-thalassemia in clonal hematopoiesis

Haematologica
Hemoglobinopathies including thalassemias are among the most frequent genetic disorders worldwide. Primarily, these entities result from germline variants in the globin gene clusters and their cis-acting regulatory elements, and thus the WHO classifies ...
Armin P. Piehler, Marietta Truger, Jan-Hendrik Kozik, Sandra Weissmann, Martin Schwonzen, Manja Meggendorfer, Wolfgang Kern, Torsten Haferlach, Gregor Hoermann, Claudia Haferlach   +9 more
doaj   +1 more source

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. [PDF]

, 2019
Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance or ...
Abruzzese, Elisabetta, Cortes, Jorge E, Hochhaus, Andreas, Hughes, Timothy P, Laneuville, Pierre, Lipton, Jeffrey H, Paar, David, Rea, Delphine, Rousselot, Philippe, Shah, Neil P, Snyder, David S   +10 more
core   +2 more sources

Etoposide‐induced cancer cell death: roles of mitochondrial VDAC1 and calpain, and resistance mechanisms

Molecular Oncology, EarlyView.
The complex mode of action of the topoisomerase II inhibitor etoposide in triggering apoptosis involves several mechanisms: overexpression of the mitochondrial protein VDAC1, leading to its oligomerization and formation of a large channel that mediates the release of pro‐apoptotic protein; and overexpression of the apoptosis regulators p53, Bax, and ...
Aditya Karunanithi Nivedita, Varda Shoshan‐Barmatz   +1 more
wiley   +1 more source